UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

Journal of clinical oncology, 2008-03, Vol.26 (8), p.1346-1354

2008

Volltextzugriff (PDF)

Chronic Liver Disease and Liver Cancer: What the Hepatologists, Oncologists, and Surgeons Want to Know from Radiologists

Magnetic resonance imaging clinics of North America, 2021-08, Vol.29 (3), p.269-278

2021

Volltextzugriff (PDF)

PET vs Sentinel Lymph Node Biopsy for Staging Melanoma: A Patient Intervention, Comparison, Outcome Analysis

Journal of the American College of Radiology, 2008-08, Vol.5 (8), p.924-931

2008

Volltextzugriff (PDF)

Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases From a Canadian Perspective

Canadian Association of Radiologists journal, 2014-02, Vol.65 (1), p.77-85

2014

Volltextzugriff (PDF)

Leukoerythroblastosis with Cytopenia as an Initial Presentation of Lung Adenocarcinoma

Case reports in oncology, 2018-05, Vol.11 (2), p.567-572

2018

Volltextzugriff (PDF)

Improving Equitable Access to Imaging Under Universal-Access Medicine: The Ontario Wait Time Information Program and Its Impact on Hospital Policy and Process

Journal of the American College of Radiology, 2010-08, Vol.7 (8), p.573-581

2010

Volltextzugriff (PDF)

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

The New England journal of medicine, 2017-11, Vol.377 (20), p.1919-1929

2017

Volltextzugriff (PDF)

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

The New England journal of medicine, 2019-02, Vol.380 (8), p.711-719

2019

Volltextzugriff (PDF)

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial

JNCI : Journal of the National Cancer Institute, 2015-02, Vol.107 (2), p.dju413-dju413

2015

Volltextzugriff (PDF)

Health-Related Quality of Life and Cost-Effectiveness Analysis in Radiology

Academic radiology, 2007-04, Vol.14 (4), p.411-419

2007

Volltextzugriff (PDF)

CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis

Academic radiology, 2009-05, Vol.16 (5), p.564-571

2009

Volltextzugriff (PDF)

Canadian Colorectal Cancer Screening Initiatives and Barriers

Journal of the American College of Radiology, 2008-09, Vol.5 (9), p.951-957

2008

Volltextzugriff (PDF)

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Annals of oncology, 2014-10, Vol.25 (10), p.1979-1987

2014

Volltextzugriff (PDF)

CT Colonography Versus Optical Colonoscopy for Screening Asymptomatic Patients for Colorectal Cancer

Academic radiology, 2009, Vol.16 (5), p.564-571

2009

Volltextzugriff (PDF)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

British journal of cancer, 2016-07, Vol.115 (2), p.188-194

2016

Volltextzugriff (PDF)

Chronic Liver Disease and Liver Cancer

Magnetic resonance imaging clinics of North America, 2021-08, Vol.29 (3), p.269-278

2021

Volltextzugriff (PDF)

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

British journal of cancer, 2016-10, Vol.115 (9), p.e13-e13

2016

Volltextzugriff (PDF)

Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

British journal of cancer, 2016-09, Vol.115 (9), p.e13-e13

2016

Volltextzugriff (PDF)

Outcome of second-line treatment (2L Tx) following nab -paclitaxel ( nab -P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC)

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.333-333

2016

Volltextzugriff (PDF)

Phase III study of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial

Journal of clinical oncology, 2015-01, Vol.33 (3_suppl), p.439-439

2015

Volltextzugriff (PDF)

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

Advances in therapy, 2017, Vol.34 (1), p.277-279

2017

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3654-3655

2008

Volltextzugriff (PDF)

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

JNCI : Journal of the National Cancer Institute, 2015-02, Vol.107 (2), p.1

2015

Volltextzugriff (PDF)

Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4027-4027

2014

Volltextzugriff (PDF)

Updated survival from a randomized phase III trial (MPACT) of nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas

Journal of clinical oncology, 2014-01, Vol.32 (3_suppl), p.178-178

2014

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Berichte
(1)

Sprache

Englisch
(28)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(12)
Radiology
(10)
Oncology
(9)
Male
(7)
Middle Aged
(7)
Evidence-Based Medicine
(6)
Female
(6)
Aged
(5)
Radiology, Nuclear Medicine & Medical Imaging
(5)
Adult
(4)
Treatment Outcome
(4)
Antineoplastic Agents - Therapeutic Use
(3)
Disease-Free Survival
(3)
Kaplan-Meier Estimate
(3)
Metastasis
(3)
Pancreatic Cancer
(3)
Prognosis
(3)
Sensitivity And Specificity
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

Chronic Liver Disease and Liver Cancer: What the Hepatologists, Oncologists, and Surgeons Want to Know from Radiologists

PET vs Sentinel Lymph Node Biopsy for Staging Melanoma: A Patient Intervention, Comparison, Outcome Analysis

Retrospective Review of Efficacy of Radiofrequency Ablation for Treatment of Colorectal Cancer Liver Metastases From a Canadian Perspective

Leukoerythroblastosis with Cytopenia as an Initial Presentation of Lung Adenocarcinoma

Improving Equitable Access to Imaging Under Universal-Access Medicine: The Ontario Wait Time Information Program and Its Impact on Hospital Policy and Process

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial

Health-Related Quality of Life and Cost-Effectiveness Analysis in Radiology

CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis

Canadian Colorectal Cancer Screening Initiatives and Barriers

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

CT Colonography Versus Optical Colonoscopy for Screening Asymptomatic Patients for Colorectal Cancer

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Chronic Liver Disease and Liver Cancer

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

Outcome of second-line treatment (2L Tx) following nab -paclitaxel ( nab -P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC)

Phase III study of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial

Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

In Reply

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC)

Updated survival from a randomized phase III trial (MPACT) of nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas

Suchergebnisse filtern